96 related articles for article (PubMed ID: 11596702)
1. Patterns of physician-reported diagnoses for women receiving raloxifene prescriptions.
Ohsfeldt RL; O'Connor LJ; Kemner JE; Solomon TE
Am J Health Syst Pharm; 2001 Oct; 58(19):1846-9. PubMed ID: 11596702
[No Abstract] [Full Text] [Related]
2. Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.
Jordan VC; Morrow M
BMJ; 1999 Aug; 319(7206):331-2. PubMed ID: 10435938
[No Abstract] [Full Text] [Related]
3. Raloxifene examined for breast cancer prevention.
Young D
Am J Health Syst Pharm; 2007 Sep; 64(17):1774. PubMed ID: 17724350
[No Abstract] [Full Text] [Related]
4. Managing menopause after breast cancer: balancing risks and benefits.
Moore HC
Cleve Clin J Med; 2001 Mar; 68(3):243-8. PubMed ID: 11263852
[TBL] [Abstract][Full Text] [Related]
5. Meeting the evolving therapeutic needs of postmenopausal women.
Ettinger B
J Bone Miner Metab; 2000; 18(5):299-304. PubMed ID: 10959621
[No Abstract] [Full Text] [Related]
6. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
7. Report examines strategies for reducing breast cancer risk.
Miller JL
Am J Health Syst Pharm; 1999 Jul; 56(13):1298. PubMed ID: 10683123
[No Abstract] [Full Text] [Related]
8. STAR trial reports.
Eur J Cancer; 2006 Aug; 42(12):1694. PubMed ID: 16998956
[No Abstract] [Full Text] [Related]
9. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women.
Walsh BW; Cox DA; Sashegyi A; Dean RA; Tracy RP; Anderson PW
Am J Cardiol; 2001 Oct; 88(7):825-8. PubMed ID: 11589863
[No Abstract] [Full Text] [Related]
10. [Treatment of postmenopausal osteoporosis with raloxifene].
Fedelesova V; Chylova K; Dzurik
Bratisl Lek Listy; 2000; 101(9):527-8. PubMed ID: 11187059
[TBL] [Abstract][Full Text] [Related]
11. Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report.
Lemmo W
Integr Cancer Ther; 2016 Sep; 15(3):245-9. PubMed ID: 27411856
[TBL] [Abstract][Full Text] [Related]
12. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
[TBL] [Abstract][Full Text] [Related]
13. Case report: raloxifene in postmenopausal women with psychosis: preliminary findings.
Wong J; Seeman MV; Shapiro H
Am J Geriatr Psychiatry; 2003; 11(6):697-8. PubMed ID: 14609815
[No Abstract] [Full Text] [Related]
14. Breast cancer hopes.
Zurlinden J
Nurs Spectr (Wash D C); 1998 Jun; 8(11):17-8. PubMed ID: 10542741
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.
Kanis JA; Borgström F; Johnell O; Oden A; Sykes D; Jönsson B
Osteoporos Int; 2005 Jan; 16(1):15-25. PubMed ID: 15672210
[TBL] [Abstract][Full Text] [Related]
16. [Specific estrogen receptor modulators (SERMs)].
Trémollières F; Lopes P
Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type.
Am J Health Syst Pharm; 1998 Jan; 55(2):104. PubMed ID: 9465969
[No Abstract] [Full Text] [Related]
18. Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women.
Christodoulakos G; Lambrinoudaki I; Panoulis C; Papadias C; Economou E; Creatsas G
Fertil Steril; 2004 Sep; 82(3):634-8. PubMed ID: 15374707
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database.
Kim J; Shin JY; Lee J; Song HJ; Choi NK; Park BJ
PLoS One; 2015; 10(6):e0127970. PubMed ID: 26030300
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene slows down the progression of intima-media thickness in postmenopausal women.
Colacurci N; Fornaro F; Cobellis L; De Franciscis P; Torella M; Sepe E; Arciello A; Cacciapuoti F; Paolisso G; Manzella D
Menopause; 2007; 14(5):879-84. PubMed ID: 17667145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
